Abstract: Medical imaging plays an important role in the clinical staging, restaging, and therapy assessment of tumors and may also serve as prognostic biomarker. Multimodal hybrid imaging technologies, such as PET/CT and recently PET/MR, have been rapidly developed in recent years. PET/CT is often recommended for the initial staging of FDG-avid lymphomas and therapy monitoring. The role of FDG PET/CT for interim therapy evaluation must be determined. Some feasibility studies indicated that using PET/MR for initial lymphoma staging is feasible. FDG PET/MR seemed to offer a comparable diagnostic performance compared with PET/CT. In this article, the research status and progress concerning multimodal hybrid imaging technologies, such as PET/CT and PET/MR, in malignant lymphoma are reviewed.